Table 1: Baseline characteristics of LN patients with and without echocardiographic LVH.

Baseline characteristicsEcho-LVH ( 𝑛 = 6 1 )Normal LVMI ( 𝑛 = 2 2 6 )

Gender, male, %8.858.20
Age, y 4 0 . 9 2 ± 1 4 . 1 6 3 5 . 4 3 ± 1 1 . 8 8
BMI, kg/m2 2 1 . 4 8 ± 3 . 1 0 2 2 . 1 0 ± 3 . 6 3
Smoke history, %17.6918.03
SBP, mmHg 1 4 0 . 0 0 ( 1 2 0 . 0 0 - 1 5 5 . 0 0 ) 1 3 0 . 0 0 ( 1 1 0 . 0 0 - 1 4 0 . 0 0 )
DBP, mmHg 8 7 . 0 0 ( 8 0 . 0 0 - 9 1 . 6 0 ) 8 5 . 0 0 ( 7 5 . 0 0 - 9 0 . 0 0 )
MABP, mmHg 1 0 3 . 3 3 ( 9 3 . 3 3 - 1 1 3 . 9 7 ) 9 8 . 3 3 ( 8 8 . 3 3 - 1 1 0 . 0 0 )
Hemoglobin level, g/L 9 0 . 6 2 ± 2 2 . 9 9 1 0 5 . 9 5 ± 2 2 . 4 3
ESR, mm/h 5 7 . 0 0 ( 2 6 . 0 0 - 8 5 . 0 0 ) 4 3 . 0 0 ( 2 1 . 0 0 - 7 3 . 0 0 )
hs-CRP, mg/L 8 . 0 3 ( 3 . 2 2 - 3 0 . 9 5 ) 3 . 9 3 ( 1 . 4 8 - 9 . 4 8 )
Serum albumin, g/L 3 0 . 0 3 ± 6 . 3 4 3 3 . 2 6 ± 6 . 0 6
Triglyceride, mmol/L 2 . 2 5 ± 1 . 1 6 2 . 4 2 ± 1 . 1 0
Cholesterol, mmol/L 5 . 4 7 ± 1 . 9 9 5 . 6 4 ± 2 . 1 2
Lipoprotein(a), mg/L 3 2 8 . 9 0 ± 4 5 . 6 2 2 7 6 . 1 4 ± 2 1 . 6 6
GFR, ml/min/1.73 m2 6 6 . 0 5 ± 4 . 6 8 9 0 . 2 4 ± 4 . 5 2
Uric acid, mmol/L 4 9 1 . 7 8 ± 2 9 . 3 5 4 0 2 . 4 4 ± 1 7 . 0 3
Calcium, mmol/L 2 . 0 7 ± 0 . 2 2 2 . 0 7 ± 0 . 2 0
Phosphate, mmol/L 1 . 5 9 ± 0 . 6 4 1 . 4 3 ± 0 . 3 6
24 hours urine protein, g/24 h 3 . 3 7 ± 2 . 2 7 3 . 0 0 ± 2 . 6 2
ds-DNA (%)32 (82.05)145 (90.06)
ANA (%)43 (91.49)180 (93.75)
ACL (%)6 (26.08)23 (17.69)
Complement C3, g/L 0 . 5 4 ( 0 . 3 8 - 0 . 8 3 ) 0 . 4 8 ( 0 . 3 7 - 0 . 6 5 )
Fibrinogen, g/L 3 . 7 7 ± 1 . 4 7 3 . 8 7 ± 1 . 4 0

Echo-LVH: echocardiographic LVH; SBP: systolic blood pressure; DBP: diastolic blood pressure; MABP: mean arterial blood pressure; ESR: erythrocyte sedimentation rate; GFR: glomerular filtration rate; ANA: antinuclear antibody; ACL antiphospholipid antibody. Case number and positive incidence of ds-DNA, ANA, and ACL was presented here in the table. Compared with normal LVMI, 𝑃 < . 0 5 , 𝑃 < . 0 1 .